Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

hare based compensation costs (see reconciliation table above and share based compensation costs details below) SG&A expenses, for the year to December 2007 increased by $171.0 million over the same period in 2006, decreasing as a percentage of product sales to 45% (2006: 52%).

For the year to December 31, 2007 SG&A included a charge of $52.7 million for share based compensation (2006: $34.4 million), which included a $22.5 million cumulative catch up charge in respect of 2005 awards, see page 18.

Depreciation and amortization

The depreciation charge for the year to December 31, 2007 was $59.3 million (2006: $43.3 million), inclusive of impairment charges of $1.8 million (2006: $0.5 million). The increase in depreciation follows investment in Shire's infrastructure to support the continuing growth of the Company.

The amortization charge for the year to December 31, 2007 was $95.0 million (2006: $57.4 million), inclusive of impairment charges of $0.4 million (2006: $1.1 million). The increased charge is primarily due to the amortization of DAYTRANA, DYNEPO and VYVANSE intangible assets following the product launches in June 2006, March 2007 and July 2007 respectively.

Integration costs

For the year to December 31, 2007 Shire incurred $1.3 million of costs associated with the integration of the New River business (2006: $5.6 million relating to the TKT acquisition). New River is now fully integrated and no further integration costs are anticipated.

Gain on sale of product rights

For the year to December 31, 2007 Shire recognized gains of $127.8 million on the sale of non-core products.

Shire received $209.6 million (net of costs of $2.2 million) from Almirall for a portfolio of non core products comprising the dermatology products SOLARAZE and VANIQA and six non-promoted products across a range of indications, which were sold by Shire primarily in the UK, France, Germany, Italy, Spain and Ireland. This sal
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 This is a ... and China Isopropanol (IPA) industry. The report provides ... applications and industry chain structure. Global market analysis ... a focus on history, developments, trends and competitive ... international and Chinese situation is also offered. , ...
(Date:9/23/2014)... New York , September 23, 2014 /PRNewswire/ ... a leading provider of  Closed System Transfer     ... new exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation. ... bodies in Taiwan , ... approval as the company continues to expand globally, ...
(Date:9/23/2014)... Greenville, SC (PRWEB) September 23, 2014 ... ) my third book on healthcare offers a three ... a 21st century healthcare delivery system that would go ... each state’s responsibility regarding the delivery of healthcare.” , ... patient safety has failed to provide discernable progress throughout ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
Breaking Biology Technology:(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and ... has received FDA clearance for the,marketing of the ATS 3f(R) ... an improved valve holder accessory device. , ... While the ATS 3f Aortic ...
... Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th ... be presented by Dr Thomas Bumm of Oregon Health and Sciences ... model of myeloproliferative disorders. , , Full ... CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induc e ...
... http://www.yourwaytransport.com ), a premium global courier that provides,customized ... biotechnology and medical/healthcare industries, today,announced that it is ... The,expansion includes a new, larger facility, enhanced web ... The company has relocated ...
Cached Biology Technology:ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3Yourway Transport Expands 2
(Date:9/23/2014)... gotten a lot greener thanks to a novel technique ... uses solar energy to accelerate tailings pond reclamation efforts ... a light source to treat oil sands process affected ... El-Din and James Bolton have found that using the ... just as efficiently but at a much lower cost. ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... soils store four times more carbon than the ... can have a big effect on atmospheric greenhouse ... Nature Climate Change concludes that climate ... or affect soil carbon storage, despite increases in ... U.S. Forest Service Research Ecologist Dr. Christian Giardina, ...
Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3Study helps assess impact of temperature on belowground soil decomposition 2
... Zoo-based Wildlife Conservation Society (WCS) warn that efforts to ... beyond must focus on better management practices on farms ... Mongolian agencies on the ground in Mongolia's Kovsgol province, ... the virus. , "We're working with our Mongolian and ...
... anyone with respiratory problems, air pollution can significantly impair ... satellites and stations on the ground to develop a ... quality forecasts. , Understanding how tropospheric or near-surface-level ozone ... region to region and continent to continent is an ...
... may have a surprisingly close-to-home answer, according to one University ... is important in obtaining clues as to where else in ... be like, said George E. Fox, a UH professor of ... research grant from NASA's Exobiology Program that seeks to understand ...
Cached Biology News:WCS says avian flu prevention should focus on farms, markets 2Sensor web simulation investigates technique to improve prediction of pollution across the globe 2Sensor web simulation investigates technique to improve prediction of pollution across the globe 3Evolution of life on Earth may hold key to finding life in outer space 2Evolution of life on Earth may hold key to finding life in outer space 3
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: